drugset / Trial / NCT04630860

A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD

NCT04630860

Phase 1 Completed 30 enrolled Luye Pharma Group Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is to evaluate the pharmacokinetics and safety of LY03003 in patients with advanced-stage PD.

Timeline

Start
2020-07-07
Primary completion
2021-05-12
Completion
2022-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject LY03003 Unknown 56 mg Intramuscular
Subject LY03003 Unknown 84 mg Intramuscular
Subject LY03003 Unknown 112 mg Intramuscular

Indications